📰 Rob Barrow News
Page 3 - Rob Barrow News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rob Barrow. Real-time updates on events, politics, business and more.
May 16, 2022
Mind Medicine(NASDAQ:NASDAQ:MNMD) Q1 2022 Earnings Conference Call May16, 2022, 08:30AM ET Company Participants Rob Barrow - CEO Dan Karlin - Chief Medical Officer Miri Halperin Wernli -...
March 4, 2022
/PRNewswire/ -- The Benzinga Psychedelics Advisory Council is a collective of the leading minds and voices in the psychedelics space, composed of key thought...
March 4, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
March 4, 2022
/PRNewswire/ -- The Benzinga Psychedelics Advisory Council is a collective of the leading minds and voices in the psychedelics space, composed of key thought...
May 17, 2021
MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial News provided by Share this article MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication NEW YORK, May 17, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting Responses from FDA leading to the finalization of the Companys clinical development...
May 5, 2021
"Evidence dating back to the 1950s suggests that LSD and other psychedelics may have analgesic effects, but this treatment area remains largely untapped by…
January 14, 2021
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience News provided by Share this article Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Office...